Overview
To provide the IRB approved mechanism for the prospective collection, analysis and reporting of data on patients who are undergoing either an autologous or allogeneic hematopoietic stem cell transplant for a disease in which a research question is not being addressed and for which peer reviewed, published data have demonstrated efficacy for this treatment approach.
Eligibility
Inclusion Criteria:
Planned standard of care dose intensive therapy and either an allogeneic or autologous bone
marrow transplant
Exclusion Criteria:
Participation in any other treatment research protocol